Dementia and Alzheimer Disease

Over a 12-week treatment period, irsenontrine was well tolerated across both amyloid positive and negative patients, with no significant difference in pharmacodynamic responses or change in central nervous system biomarkers.

Results from a longitudinal study suggest that higher proportions of subjective memory decline are associated with insomnia disorder in middle-aged and older adults.

The president and chief executive officer of INmune Bio detailed the mechanistic advantages of XPro1595 as a potentially therapeutic benefit for patients with Alzheimer disease and dementia. [WATCH TIME: 5 minutes]

Over a 6-month period, percent change and mean change in brain amyloid levels significantly favored donanemab over aducanumab (Aduhelm; Biogen).

An ongoing phase 1b/2a clinical trial showed that both the ACI-35.030 and JACI-35.054 vaccines are safe as a treatment for patients in the earlier stages of Alzheimer disease, the authors suggested ACI-35.030 suggested as the superior vaccine candidate.

The assistant professor, Rutgers University, New Brunswick, New Jersey, offers an overview on her ongoing lab project about a music-based intervention to improve insomnia in dementia and caregivers. [WATCH TIME: 3 minutes]

In the pivotal phase 3 Clarity AD trial, lecanemab (Biogen) demonstrated significant impacts on primary and secondary end points, with additional promising results on biomarker analyses and safety.

Treatment with the investigational agent resulted in improvements in Alzheimer disease agitation, as well as significant delays in time to relapse and prevention of relapse.

The president of the International Neuropalliative Care Society detailed potential disease states that could benefit from neuropalliative care as well as the importance of the patient community in expanding this type of approach. [WATCH TIME: 4 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is sleep disorders.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 25, 2022.

The president of the International Neuropalliative Care Society provided perspective on the growth of the field of neuropalliative care, the organization’s role, and how clinicians are overcoming current barriers in place.

The president of the International Neuropalliative Care Society discussed the area in which neuropalliative has expanded and improved, as well as the potential in the coming years. [WATCH TIME: 2 minutes]

The president of the International Neuropalliative Care Society provided an overview of the organization’s recently concluded conference and the significance of the growth of neuropalliative care. [WATCH TIME: 6 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is neuromuscular disorders.

ACU193, an antibody developed based on its selectivity for soluble amyloid-ß oligomers, is currently being assessed in a phase 1 trial, with a potential phase 2/3 trial in the near future.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 18, 2022.

Darina Petrovsky, PhD, RN, assistant professor, Rutgers University, spoke about her current study focused on developing a music-based application for people with dementia and their caregivers who have trouble sleeping.

The GRADUATE studies, which spanned across 32 countries, showed minimal relative reduction in clinical decline for those on gantenerumab relative to placebo over a 116-week treatment cycle.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is neuromuscular disorders.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 11, 2022.

Available neurodegenerative disease treatments are generally unsafe and ineffective at penetrating the blood-brain barrier, though the use of nanoparticles can provide improved penetration and exert a neuroprotective effect.

The Palatucci Advocacy Leadership Forum, or PALF, sponsored by the American Academy of Neurology, gives neurologists and trainees tools to successfully advocate for their ideas and develop their identity as physician advocates.

SCI-110 not only met its primary safety end points, but the agent showed benefits on secondary outcomes such as need to use rescue medication and exploratory outcomes such as appetite.

Acting as an advocate is meaningful to neurologists because it speaks to their inner core—or their “why.” Neurologists have the agency to make this world a better place while working as a neurologist and an advocate at many levels.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is headache and migraine.